We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

5,000 Open access books available
124,000 International authors and editors
140M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Clinical Features of Skin

Dilek Biyik Ozkaya
Department of Dermatology, Vakif Gureba Teaching Hospital, Istanbul, Turkey

1. Introduction

1.1 Cutaneous sarcoidosis
Sarcoidosis is a multisystem granulomatosis disease of unknown etiology, characterized pathologically by noncaseating granulomas in involved tissues. It mainly involves the lungs but may also be associated with systemic manifestations. The disease most commonly affects the lungs, lymph nodes, liver, spleen, phalangeal bones, parotid glands, eyes, and skin. Skin involvement rarely causes significant morbidity or mortality. However, it can adversely affect a patient’s quality of life by causing cosmetic impairment.

1.2 History
Sarcoidosis is first described by Sir Jonathan Hutchinson in 1875. In 1889 the dermatologist Besnier described lupus pernio (sarcoidosis of the face) as a variant of cutaneous sarcoidosis. In 1899, Boeck described benign sarcoid and miliary lupoid.

1.3 Epidemiology
Sarcoidosis occurs worldwide and affects all ages and races. Disease onset is most often in the third decade of life, although a smaller second peak occurs in people older than 50 years.

1.4 Etiology and pathogenesis
The cause of sarcoidosis is unknown. It has been suggested that sarcoidosis is a hypersensitivity reaction caused by prolonged exposure to a specific antigen. Although a specific antigen has not yet been identified for sarcoidosis, the immune response which leads to recognizable clinical lesions and functional impairment is of the type 1 variety: elevated IFN gamma, IL-2, and Th1 immune regulatory monokine IL2 characterize sarcoidosis. Although mycobacteria have not been identified with traditional methods, mycobacterial DNA has been found in sarcoidal lesions. Infectious agents such as mycobacteria, propionibacterium acne and Chlamydia have been associated with sarcoidosis. The etiologic role of various chemicals and metals such as beryllium, aluminium, zirconium, and titanium has also been debated. Treatment with interferons can cause a variety of inflammatory conditions, including sarcoidosis. Genetic susceptibility to sarcoidosis has been associated with HLA -1, HLA-B8, and HLA-DR3 alleles.
1.5 Cutaneous lesions
Sarcoidosis involves so many organs that it is difficult to describe all the features. About 40-50% of patients have cutaneous involvement. Lesions are divided into two: specific and nonspecific skin lesions.

Skin lesions that contain typical sarcoid granulomas histologically are classified as specific lesions. Nonspecific skin lesions are those with nondiagnostic inflammatory patterns; the most common is erythema nodosum. Nonspecific skin lesion lack typical noncaseating granulomas.

1.5.1 Specific lesions
The specific lesions of sarcoidosis all contain granulomas histologically, but the clinical appearance of the lesions is inconsistent. Specific lesions of sarcoidosis can present as macules, papules, plaques, nodules, and ulcerations. The involved skin may be skin colored, hyperpigmented, hypopigmented, or violaceous in color. Epidermal changes of the lesions may include atrophy, scaling, telangiectasias, or none at all. Specific sarcoidal lesions most often are found on the head and neck, and but may occur symmetrically or asymmetrically on any part of the skin and mucosa.

1.5.1.1 Papules and plaques
The most common presentation is papular form. Papules are elevated skin lesions less than 5mm in size. They have a predilection for the face and especially common around the eyes and on the posterior neck. They may be skin colored, hyperpigmented, erythematous, hypopigmented, violaceous, but classically they are described as having a yellow–brown hue with an erythematous background. When pressure is applied with a glass slide or a dermoscope the erythematous coloration is mitigated and the yellow-brown color (often described as the color of apple jelly) can be more easily appreciated. The apple jelly appearance and nodules are not pathognomonic for sarcoidosis, as other granulomatous skin conditions, such as lupus vulgaris may exhibit similar diascopic properties.

The plaques form of sarcoidosis is rare and involves the extremities, the face and the corpus. Plaques may arise denova or from a confluence of papules. These lesions are larger than 5mm in diameter. Lupus pernio describes the relatively symmetric, violaceous, indurated plaques that occur on the nose, ear-lobes, cheeks and digits. This clinical variant of sarcoidosis is distinctive and has been associated with symmetric involvement. Lupus pernio is associated with a higher prevalence of upper respiratory tract disease.
1.5.1.2 Scar sarcoidosis

Cutaneous sarcoidosis occurring in prior scar tissue, at traumatized areas of skin, or around foreign bodies such as tattoos is common. Scars become inflamed and infiltrated with sarcoidal granulomas. Inflammation of old scars may parallel or precede systemic disease activity. The presence of foreign body in granuloma does not exclude sarcoidosis entirely. Many cases of scar sarcoidosis are following car accidents in which there is exposure to glass and dirt.

1.5.1.3 Scalp

Alopecia occurs with the involvement of the scalp. Scalp sarcoidosis may cause irreversible cicatrical or noncicatrical sarcoidosis. Biopsy shows noncaseating granulomas. Its reversibility depends on the degree of the destruction of hair follicles.
1.5.1.4 Nail
Sarcoidal inflammation around the nail matrix or within the distal bones of the digits can cause nail abnormalities. Nail plate deformation and discoloration, clubbing, subungual hyperkeratosis may be seen. The incidence of hair and nail involvement is very low.

1.5.1.5 Mucous membranes
Sarcoidal granulomas may cause papules and plaques of the mucosal membranes and the tongue. Sarcoidosis may cause Mikulicz syndrome.

1.5.1.6 Ulcerations
The cutaneous lesions of sarcoidosis very rarely ulcerate. The most common site is the legs. These lesions may mimic other ulcerative conditions such as venous stasis ulcerations, but they have granulomas present histologically. An ulcerated necrobiosis lipoidica diabeticorum must also be considered.

1.5.1.7 Subcutaneous nodules
When the sarcoidal granulomas situated in the adipose tissue the skin induces clinically evident subcutaneous nodules and the classic red-brown color may not be seen. Instead the overlying skin may be normal or slightly red. Multiple rather than solitary lesions are usually present. This granulomatous panniculitis is known as Darier–Roussy sarcoidosis.

1.5.1.8 Angiolupoid sarcoidosis (Brocq and pautrier)
This form of chronic cutaneous sarcoidosis is features red Brown papules, nodules, an plaques with prominent telangiectasies that tend to involve the mid face of the women. In such cases, it is important to consider the rare granuloma eosinophilicum faciei as well as pseudolymphoma.

1.5.1.9 Macular
Cutaneous sarcoidosis may present as hypopigmented nonelevated areas. This variant is more common in dark skinned patients.

1.5.1.10 Additional presentations
Lots of additional presentations have been reported. These includes erythroderma, ichthyosiform, rosacea like type, psoriasiform, morpheaform plaques, lichenoid
dermatitis, folliculitis-like lesions, gyrate erythema, penile and vulvar lesions, palmar erythema, discoid lupus-like plaques, lower extremity edema, lesions mimicking polymorphous light eruption.

1.5.2 Nonspecific lesions

1.5.2.1 Erythema nodosum
This is the most common nonspecific lesion. In most parts of the world, it is necessary to exclude sarcoidosis when erythema nodosum is diagnosed in adults. The lesions of erythema nodosum are tender and found predominantly on the lower extremities as well. The anterior surface of the lower leg is the most common location. The presence of bilateral hilar adenopathy on chest radiograph with erythema nodosum is known as Löfgren syndrome.

Other nonspecific lesions are seen very rare. Prurigo nodules, erythema multiforme, lower extremity swelling, Sweet syndrome and pyoderma gangrenosum qualify as nonspecific cutaneous sarcoid lesions.

1.6 Treatment
The treatment of cutaneous sarcoidosis has been usually derived from agents for pulmonary sarcoidosis. Standard therapeutic interventions for cutaneous sarcoidosis have traditionally included topical, intralesional and systemic corticosteroids, antimalarial drugs, methotrexate, and combinations of these agents.

1.6.1 Corticosteroids
Corticosteroids are the worldwide accepted standard treatment of sarcoidosis. For the patients with mild limited sarcoidosis the treatment may start with using ultrapotent topical corticosteroids. Intralesional injections have been useful for some cases. The concentration of the corticosteroids selected depends on the firmness and size of the lesion, but most lesions of sarcoidosis may be treated initially with intralesional triamcinolone at concentrations of 3-20 mg/mL repeated every 4 weeks until the lesions have flattened. Adverse effects are hypopigmentation and atrophy. Systemic corticosteroid therapy, usually delivered orally, should be reserved for severely disfiguring or destructive lesions, widespread involvement, or lesions that have proved refractory to localized therapy. The dosage of prednisone administered ranges from 40 to 80 mg/prednisone administered ranges from 40 to 80 mg/day and is tapered over weeks to months depending on the clinical response.

1.6.2 Antimalarial agents
The effectiveness of chloroquine and hydroxychloroquine in sarcoidosis is thought to be related to the ability of these agents to inhibit antigen processing and presentation to CD4 T cells. They have anti-inflammatory properties. The rate of response appears to be higher for cutaneous compared with pulmonary sarcoidosis. These drugs have been widely used for cutaneous sarcoidosis. Maximum oral chloroquine dosage is 3.5 mg/kg/day and hydroxychloroquine dosage is 6.5 mg/kg/day. Lower dosages are effective and are preferred to maximal dosing. The toxicities of antimalarials are nausea, anorexia, dizziness, headaches and blurred vision. Bleaching of the hair, agranulocytosis.
Agranulocytosis is rare but serious complication of therapy. Potential ocular effects are the most serious adverse events associated with antimalarial treatment and include the development of corneal deposits of central retinopathy.

1.6.3 Methotrexate
Methotrexate is a folate analogue that inhibits dihydrofolate reductase. At high doses methotrexate is antiproliferative, in low doses methotrexate has antiinflammatory properties.

The dose of methotrexate is varies. In adults, the average starting dosage is 10 to 15mg a week. Hepatotoxicity is the major long-term effect associated with methotrexate, and routine monitoring of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and serum albumine is recommended. While using methotrexate the patients must be monitored for neutropenia. Methotrexate is cleared with kidneys; because of this serum creatinine monitoring must be done.

Methotrexate is associated with hematologic, gastrointestinal, pulmonary and hepatic toxicities. Dose dependent toxicities are mucositis, mouth sores, and nausea. These problems can be eliminated by dividing the dose of methotrexate in half and giving oral folate.

1.6.4 Combination standard therapy
Antimalarials and corticosteroids can be used in sequence. By this way complications of the long term use can be reduced. Steroids and antimalarials are steroid sparing agents. Both of them can be used in place of steroid or in combination with steroids. Combination therapies have the advantage of decreasing steroid doses.

1.6.5 Other therapies
Pentoxifylline, tetracyclines, Leflunomide, Thalidomide, Infliximab, Chlorambucil, cyclosporin-A, allopurinol, laser surgery are reported for the treatment of sarcoidosis.

2. References
[1] Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003, 361(9363):1111-1118
[2] Marchell RM, Judson MA. Cutaneous Sarcoidosis. Semin Respir Crit Care Med. 2010 Aug;31(4):442-51
[3] Yamamoto M, Sharma OP, Hosodo Y, Special report-The descriptive definition of sarcoidosis. Sarcoidosis 9:33-34, 1992
[4] Georgi Tchernev; Cutaneous Sarcoidosis: The ‘Great Imitator’. Am J Clin Dermatol 2006;7(6):375-82
[5] Richard M, Marchell, Marc A. Judson Cutaneous Sarcoidosis Semin Respir Crit Care Med. 2010 Aug;31(4):452-51
[6] Amy H., Clifton R.W Non infectious Granulomas. Dermatology. Jean I Bolognia, Joseph L Jorizzo, Ronald P Rapini First edition. Edinburgh, 2003, Mosby, 1455-60
[7] American Thoracic Society/ European Respiratory Society: Statement on sarcoidosis, Joint Statement of the American Thoracic Society(ATS), the European Respiratory Society(RS) and the world Association of Sarcoidosis and Other
Clinical Features of Skin

Granulomatous Diseases adopted by the ATS Board of directors and the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160:736,1999

[8] Kyra A Oswald-Richter, Dia C Beachboard, Xiaoan Zhan et al. Respir Res. 2010 November 23. Doi 10.1186/1465-9921-11-161

[9] Christy B., Ted R. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 56 (1):69-81

[10] Sergij Goert Granulomatous Diseases. Burgdorf Plewiger Wolff Landthaler Third edition Springer Medizin Verlag Heidenberg Braun -Falco’s Dermatology 548-555

[11] Richard M Marchell, Bruce Thiers, Marc A. Judson Sarcoidosis. Klaus Wolff , Lowell A. Goldsmith,Stephen I . Katz et al.seventh edition,2008 Fitzpatrick’s Dermatology in General Medicine, 1484-1493

[12] Greer KE,Harman LE Jr, Kayne AL.Unusual cutaneous manifestations of sarcoidosis. South Med J 1977;70:666-668

[13] Cather JC, Cohen PR. Ichthyosiform sarcoidosis. J Am Acad Dermatol 1999;40(5 Pt 2):862-65

[14] Weber FP, Lauber HK Proc R Soc Med. 1939 Jul;32(9):1024-5

[15] Burgoyne JS, Wood MG. Psoriasiform sarcoidosis. Br J Dermatol 1984;111:52

[16] Choi SC, Kim CR, Lee DY, Lee ES, Yang JM. Ann Dermatol. 2010 Aug;22(3):316-8. Epub 2010 Aug 5

[17] Goldberg LJ, Goldberg N, Abrahams I, Silvers DN, Szaniawski W, Halperin AJ. Giant Cell lichenoid dermatitis: a possible manifestation of sarcoidosis

[18] Robert P., Baughman , Elyse E. Lower Evidence -based therapy for cutaneous sarcoidosis. Clinics in Dermatology (2007) 25,334-340

[19] Christy B.,Ted R Evidence- Based Therapy for Cutaneous Sarcoidosis Drugs, 2008;68(10):1361-1383

[20] Park MK, Fontana Cr, Babaali H,Gilbert-Mcclain LI, Stylianou M, Joo J, Moss J, Mangasekli VC. Steroid sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):121-131

[21] Park DJ, Woog JJ, Pulido JS, Cameron JD. Minocycline for the treatment of ocular and adnexal sarcoidosis. J Am Acad Dermatol. 2006 Feb;54(2):258-65

[22] Sapadin AN,Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006 Feb;54(2):258-65

[23] Baughman RP, Lower EE. Leufunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Disease. 2004 Mar;21(1):43-8

[24] Hammond ER,Kaplin AL,Kerr DA.Spinal Cord.2007 Dec;45(12):802 Epub 2007 Aug 21

[25] Augiar M, Marcal N, Mendes AC, Bugalho de Almeida A. Infliximab for treating sarcoidosis patients. Portuguese experience. Rev port Pneumol. 2011 Apr;17(2):85-93

[26] Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis.1991 Mar;8(1):35-41

[27] Manzia TM, Bellini MI, Corona L,Frantoni S, Cillis A, Orlando G, Tisone G. Successfull treatment of systemic de nova sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl int 2011 Apr 19. doi:10.1111/j.1432-2277
[28] Bregnhoej A, Jemec GB. Low-dose allopurinol in the treatment of cutaneous sarcoidosis: response in four of seven patients. J Dermatolog Treat. 2005 Apr; 16(2): 125-7

[29] Ross S, Raulin C, Ockenfels HM, Karsai S. Successful treatment of cutaneous sarcoidosis lesions with the flashlamp pumped pulsed dye laser: a case report. Dermatol Surg. 2009 Jul; 35(7): 1139-40
Sarcoidosis is a type of inflammation that occurs in various locations of the body for no known reason. Normally, when foreign substances or organisms enter the body, the immune system will fight back by activating an immune response. Inflammation is a normal part of this immune response, but it should subside once the foreign antigen is gone. In sarcoidosis, the inflammation persists, and some of the immune cells form abnormal clumps of tissue called granulomas. The disease can affect any organ in the body, but it is most likely to occur in the lungs. It can also affect the skin, eyes, liver, or lymph nodes. Although the cause of sarcoidosis is not known, research suggests that it may be due to an extreme immune response or extreme sensitivity to certain substances. It also seems to have a genetic component as well, and tends to run in families. Sarcoidosis most commonly develops in people between 20 and 50 years of age. African Americans are somewhat more likely to develop sarcoidosis than Caucasians, and females are somewhat more likely to develop sarcoidosis than males. The symptoms of sarcoidosis depend on the organ involved. This book deals with the diagnosis and treatment of this mysterious disease of unknown etiology.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Dilek Biyik Ozkaya (2011). Clinical Features of Skin, Sarcoidosis Diagnosis and Management, Prof. Mohammad Hosein Kalantar Motamedi (Ed.), ISBN: 978-953-307-414-6, InTech, Available from: http://www.intechopen.com/books/sarcoidosis-diagnosis-and-management/clinical-features-of-skin
© 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.